The largely parallel results observed in Fig 2 for culture-expanded human vs. dog ICs support our hypothesis that the NI technology, already demonstrated to eliminate or reduce the need for insulin in diabetic mice and dogs, respectively, possesses substantial translational promise for its clinical testing and treatment of human T1DM. This evidence concerns the gene INS and type 1 diabetes mellitus.